Cancer (Solid Tumors)NCT07104955
Salutare One Referral Software Impact on Multi-Disciplinary Team (MDT) Meetings Effectiveness and Safety
A study testing MDT referral and review software in people with Cancer (Solid Tumors) and Sarcoma, run by Salutare Group Ltd. at 1 site in United Kingdom.
Trial summary
Multi-Disciplinary Team (MDT) meetings are crucial for planning patient care in the National Health Service (NHS), but they can be time-consuming and sometimes lack complete patient information. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Cancer (Solid Tumors), Sarcoma
- What is being tested?
- MDT referral and review software
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 40 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 31 Jul 2025to 19 Jul 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- MDT meeting Panel Members, Coordinators and staff submitting MDT referrals will take part in this study.
Who cannot join
- MDT meeting Panel Members, Coordinators and staff submitting MDT referrals who are unwilling or unable to take part in the study.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United Kingdom1 site, 1 recruiting
- Recruiting
Royal National Orthopaedic Hospital
London, HA7 4LP
Rachel Baumber, MD, +442039470100, rachel.baumber@nhs.net
About this study
Official title: Single Cohort Before and After Mixed-methods Prospective Study to Investigate the Impact of the Salutare One Referral Software on Patient Outcomes, Safety and Effectiveness of Multi-Disciplinary Team (MDT) Meetings
Multi-Disciplinary Team (MDT) meetings are crucial for planning patient care in the National Health Service (NHS), but they can be time-consuming and sometimes lack complete patient information. This can lead to delays in treatment decisions, potentially incomplete care plans, or the need to repeatedly discuss the same patient cases.
This study aims to test a new software called Salutare One Referral. One Referral is designed to make these meetings more efficient and effective. We want to see if this software can help healthcare staff prepare MDT referral information more easily and facilitate a more informed MDT discussion, which could lead to better patient care. If successful, this could help improve how MDTs operate across the NHS.
Read the detailed description
This study aims to evaluate the safety, implementation effectiveness and feasibility of the Salutare One Referral software, a new tool designed to enhance Multi-Disciplinary Team (MDT) meetings. MDT meetings are recognized as the preferred means of delivering complex care for both chronic and acute diseases. However, there remains significant diversity in the purpose, structure, processes, and content of MDT meetings, as well as in how effectively they have been integrated into clinical practice.
Common issues observed in MDTs include:
- Deferring discussions due to incomplete medical history
- Re-discussing the same cases due to inadequate recording of previous discussions
- Failure to systematically manage cases to meet local and national targets The Salutare One Referral software is designed to address these challenges by streamlining the referral process, improving information sharing, and enhancing decision-making processes in MDT meetings. By potentially enhancing MDT efficiency, this study could lead to faster and better-coordinated patient care, reducing delays in treatment planning and implementation.
Study Design: This is a "before and after" study, observing MDT operations without the software, then with the software, followed by another period without it. MDT members will use the Salutare One Referral software during their regular meetings and complete questionnaires about their experience. The study will also analyse pseudonymized patient data to assess any changes in MDT review effectiveness. If successful, this study could lead to more efficient and effective MDT meetings, potentially resulting in improved patient care coordination across the NHS.
- Conditions
- Cancer (Solid Tumors), Sarcoma
- Being tested
- MDT referral and review software
- Keywords
- digital health, digital health intervention, multi-disciplinary team meeting, MDT, digital health technology, referral, software
- Medical subject headings
- Neoplasms, Sarcoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MDT referral and review softwareOther
Use of the multi-disciplinary team (MDT) meeting software to submit, review and discuss referrals
| Study group | Role | What they receive |
|---|---|---|
| One Referral Group | Other | The study arm activities include:
1. Pre-intervention phase: standard multi-disciplinary (MDT) process (without One Referral), baseline MDT meeting observation data collection, participants confirm informed consent and complete baseline survey.
2. Onboarding phase: participants receive training on how to use the One Referral software and complete onboarding survey..
3. Intervention phase: One Referral software is used as part of the MDT referral and review processes, MDT meeting observation data collection, participants complete intervention survey.
4. Post-intervention phase: standard MDT process (without One Referral), follow-up MDT meeting observation data collection, participants complete offboarding survey Receives: Other: MDT referral and review software |
What is being measured
The primary outcome is the main question the study is designed to answer.
One Referral system safety in facilitating effective MDT meetings
MDT panel participant feedback on safety and operational incidents
Measured: 8 weeks (4 MDT meetings) for complex MDTs or 4 weeks (8 MDT meetings) for high-volume MDTs
One Referral system implementation feasibility in facilitating effective MDT meetings
MDT panel participant feedback on effectiveness (non-validated questionnaire)
Measured: 8 weeks (4 MDT meetings) for complex MDTs or 4 weeks (8 MDT meetings) for high-volume MDTs
One Referral system acceptability to MDT panel members acceptability in facilitating
MDT panel participant feedback on acceptability (Software Usability Scale 0-100, higher score indicate a better outcome)
Measured: 8 weeks (4 MDT meetings) for complex MDTs or 4 weeks (8 MDT meetings) for high-volume MDTs
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Aug 2025
- Study start31 Jul 2025
- Primary completion19 Jun 2026 (estimated)
- Study completion19 Jul 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cancer (Solid Tumors)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Prospective Before and After Study
- Masking
- None (open label)
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Salutare Group Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Kevin Moore, MD, Principal investigator, Salutare Limited
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07104955
- Sponsor's protocol ID
- Salutare 01/2024
- Other IDs
- IRAS 347710
- Status last verified
- Aug 2025
- First submitted
- 18 Jun 2025
- Last updated
- 5 Aug 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Participant consent provided for sharing de-identified data for the purpose of future research. Requests should be submitted to the sponsor and will be considered in line with the sponsor policy.
Study at a glance
From the registry record, last updated by the sponsor on 5 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Single Cohort Before and After Mixed-methods Prospective Study to Investigate the Impact of the Salutare One Referral Software on Patient Outcomes, Safety and Effectiveness of Multi-Disciplinary Team (MDT) Meetings
- ClinicalTrials.gov ID
- NCT07104955
- Acronym / sponsor ID
- Salutare 01/2024
- Conditions
- Cancer (Solid Tumors), Sarcoma
- Keywords
- digital health, digital health intervention, multi-disciplinary team meeting, MDT, digital health technology, referral, software
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- Salutare Group Ltd.Industry (pharma, biotech, devices)
- Study start
- 31 Jul 2025 (actual)
- Primary completion
- 19 Jun 2026 (estimated)
- Study completion
- 19 Jul 2026 (estimated)
- First posted
- 5 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Multi-Disciplinary Team (MDT) meetings are crucial for planning patient care in the National Health Service (NHS), but they can be time-consuming and sometimes lack complete patient information. This can lead to delays in treatment decisions, potentially incomplete care plans, or the need to repeatedly discuss the same patient cases.
This study aims to test a new software called Salutare One Referral. One Referral is designed to make these meetings more efficient and effective. We want to see if this software can help healthcare staff prepare MDT referral information more easily and facilitate a more informed MDT discussion, which could lead to better patient care. If successful, this could help improve how MDTs operate across the NHS.
Detailed description
This study aims to evaluate the safety, implementation effectiveness and feasibility of the Salutare One Referral software, a new tool designed to enhance Multi-Disciplinary Team (MDT) meetings. MDT meetings are recognized as the preferred means of delivering complex care for both chronic and acute diseases. However, there remains significant diversity in the purpose, structure, processes, and content of MDT meetings, as well as in how effectively they have been integrated into clinical practice.
Common issues observed in MDTs include:
- Deferring discussions due to incomplete medical history
- Re-discussing the same cases due to inadequate recording of previous discussions
- Failure to systematically manage cases to meet local and national targets The Salutare One Referral software is designed to address these challenges by streamlining the referral process, improving information sharing, and enhancing decision-making processes in MDT meetings. By potentially enhancing MDT efficiency, this study could lead to faster and better-coordinated patient care, reducing delays in treatment planning and implementation.
Study Design: This is a "before and after" study, observing MDT operations without the software, then with the software, followed by another period without it. MDT members will use the Salutare One Referral software during their regular meetings and complete questionnaires about their experience. The study will also analyse pseudonymized patient data to assess any changes in MDT review effectiveness. If successful, this study could lead to more efficient and effective MDT meetings, potentially resulting in improved patient care coordination across the NHS.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Prospective Before and After Study
| Arm | Type | Receives |
|---|---|---|
| One Referral Group | Other | Other: MDT referral and review softwareThe study arm activities include: 1. Pre-intervention phase: standard multi-disciplinary (MDT) process (without One Referral), baseline MDT meeting observation data collection, participants confirm informed consent and complete baseline survey. 2. Onboarding phase: participants receive training on how to use the One Referral software and complete onboarding survey.. 3. Intervention phase: One Referral software is used as part of the MDT referral and review processes, MDT meeting observation data collection, participants complete intervention survey. 4. Post-intervention phase: standard MDT process (without One Referral), follow-up MDT meeting observation data collection, participants complete offboarding survey |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (1 listed)
- MDT meeting Panel Members, Coordinators and staff submitting MDT referrals will take part in this study.
Key exclusion criteria (1 listed)
- MDT meeting Panel Members, Coordinators and staff submitting MDT referrals who are unwilling or unable to take part in the study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MDT referral and review softwareUse of the multi-disciplinary team (MDT) meeting software to submit, review and discuss referrals | Other | One Referral Group |
Primary outcome
One Referral system safety in facilitating effective MDT meetings
Time frame: 8 weeks (4 MDT meetings) for complex MDTs or 4 weeks (8 MDT meetings) for high-volume MDTs
MDT panel participant feedback on safety and operational incidents
One Referral system implementation feasibility in facilitating effective MDT meetings
Time frame: 8 weeks (4 MDT meetings) for complex MDTs or 4 weeks (8 MDT meetings) for high-volume MDTs
MDT panel participant feedback on effectiveness (non-validated questionnaire)
One Referral system acceptability to MDT panel members acceptability in facilitating
Time frame: 8 weeks (4 MDT meetings) for complex MDTs or 4 weeks (8 MDT meetings) for high-volume MDTs
MDT panel participant feedback on acceptability (Software Usability Scale 0-100, higher score indicate a better outcome)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Aug 2025.
- Individual participant dataSharing planned: Yes. Participant consent provided for sharing de-identified data for the purpose of future research. Requests should be submitted to the sponsor and will be considered in line with the sponsor policy.
Related trials for Cancer (Solid Tumors)
RecruitingPhase 2
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Carcinoma, Non-small-Cell Lung
RecruitingPhase 1
A Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors
Advanced Stage Solid Tumors
RecruitingPhase 1/2
A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors
Hepatocellular Carcinoma (HCC), Metastatic Uveal Melanoma
RecruitingPhase 1
A Study of JNJ-1761981 in Participants With Solid Tumors
Neoplasms
Not yet recruitingPhase 1
GD2IL18CART Combined With Bevacizumab for Relapsed and Refractory GD2-positive Solid Tumors
Neuroblastoma (NBL), Ewing Sarcoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Kevin Moore, MD principal investigator
Salutare Limited
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing MDT referral and review software in people with Cancer (Solid Tumors) and Sarcoma, run by Salutare Group Ltd. at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 5 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Liba Stones, MA, MBA (+447443940319, liba@dicro.co.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
One Referral system safety in facilitating effective MDT meetings (time frame: 8 weeks (4 MDT meetings) for complex MDTs or 4 weeks (8 MDT meetings) for high-volume MDTs). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Aug 2025.